The U.S. Food and Drug Administration indicated that a premarket approval application seeking to allow the Lutonix drug-coated balloon to treat peripheral artery disease below the knee is “not approvable in its current form,” BD Chairman and CEO Vincent A. Forlenza told investors last week.